目的 探讨聚普瑞锌颗粒联合铝碳酸镁片治疗胆汁反流性胃炎(bile reflux gastritis, BRG)伴肠化生的临床疗效及对胃黏膜肠化生病理组织学的影响。方法 选取在武警重庆总队医院治疗的BRG伴肠化生76例患者为研究对象,随机数字表法分为观察组和对照组,每组38例。所有患者均经过胃镜及病理活检确诊。对照组给予铝碳酸镁片治疗,观察组在对照组的基础上加用聚普瑞锌颗粒治疗。比较两组患者治疗前后症状评分、胃镜评分、胃黏膜慢性炎性反应病理组织学评分、肠化生改善及不良反应发生情况。结果 治疗后观察组症状评分、胃镜评分、胃黏膜慢性炎性反应病理组织学评分显著低于对照组,差异有统计学意义(P＜0.05)。治疗后观察组肠化生病理组织学评分[(1.41±0.63)分]与对照组[(1.79±0.59)分]比较,差异有统计学意义(P＜0.05),观察组肠化生改善率为52.6%,显著高于对照组的15.8%,差异有统计学意义(P＜0.05),两组均未见严重不良反应,差异无统计学意义。结论 聚普瑞锌颗粒联合铝碳酸镁片能改善胆汁反流性胃炎伴肠化生患者临床症状及胃黏膜病理组织学形态。
Abstract
Objective To investigate clinical effect of polaprezine granules combined with hydrotalcite tablets in treatment of bile reflux gastritis(BRG) with intestinal metaplasia.Methods Seventy-six patients with BRG with intestinal metaplasia were included in this study. They were selected to be divided into observation group and control group via the random number table,with 38 cases in each. They were all diagnosed by endoscopy and BRG with intestinal metaplasia were diagnosed by pathological examination.The control group was treated with hydrotalcite tablets,while the observation group additionally received polaprezine granules based on the control group. Before and after therapy,differences of symptoms cores,gastroscopy cores and gastric mucosa chronic inflammation pathological histology score , improvement rate of intestinal metaplasia ,and incidence of adverse drug reactions between two groups were compared.Results After treatment,the symptoms cores,gastroscopy cores and gastric mucosa chronic inflammation pathological histology score were significantly lower than those in control group,with statistically significant difference(P<0.05). The gastric mucosa intestinal metaplasia score of observation group were higher than those in control group with statistically difference(1.41±0.63 vs. 1.79±0.59, P<0.05). The improvement rate of intestinal metaplasia was 52.6%(20/38)in observation group and 15.8%(6/38)in control group, so the difference was statistically significant(P<0.05).There was no severe adverse drug reaction in both group and no statistically significant difference between them.Conclusions Polaprezine granules combined with hydrotalcite tablets can improve clinical symptoms and prognosis of gastric mucosa pathology of BRG with intestinal metaplasia.
关键词
铝碳酸镁 /
聚普瑞锌 /
胆汁反流性胃炎 /
肠化生
Key words
hydrotalcite /
polaprezine /
bile reflux gastritis /
intestinal metaplasia
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 周银斌,陈东风.胆汁反流性胃炎研究现状[J].胃肠病学与肝病学杂志,2019,28(6):689-691.
[2] 中华医学会,中华医学会消化病学分会,中华医学会全科医学分会等.慢性胃炎基层诊疗指南(2019年)[J].中华全科医师杂志,2020,19(9):768-775.
[3] 苏保伟,王景杰.胆汁反流性胃炎发病机制及其肠化生分子作用机制研究进展[J]. 陕西医学杂志, 2020,49(9):1199-1201.
[4] 荀林娟,宋瑞梅,庄 英,等.胆囊切除术后胆汁反流性胃炎的研究进展[J].实用临床医药杂志,2018,22(1):146-148.
[5] 韩美玲,林轲羽,牛海静.胆汁酸在食管腺癌发生发展中作用的研究进展[J].中华实验外科杂志,2020,37(5):985-989.
[6] 陈 健,闫 滢,钱小军,等.基于临床病理特征构建胃癌根治术后早期复发风险预测模型 [J].武警医学,2019,30(9):776-779.
[7] Gomez J M, Wang A Y. Gastric intestinal metaplasia and early gastric cancer in the west: a changing paradigm [J]. Gastroenterol Hepatol(NY) , 2014, 10(6):369-378.
[8] Choi A Y, Strate L L, Fix M C,et al . Association of gastric intestinal metaplasia and east asian ethnicity with the risk of gastric adenocarcinoma in a U. S. population[J].Gastrointest Endosc, 2018, 87(4) : 1023-1028.
[9] 玉 珍,戴 芸.美国胃肠病协会临床实践指南解读:胃黏膜肠上皮化生的管理(2019 年)[J].中华临床医师杂志(电子版),2020,14(3):166-169.
[10] 汪晓柏,方清流.莫沙必利、埃索美拉唑和铝碳酸镁治疗BRG患者的效果分析[J]. 河北医药,2019,41(17):2610-2616.
[11] 王 征,钱家鸣.胃黏膜保护剂聚普瑞锌的应用进展[J].中华消化杂志,2018,38(8):571-573.
[12] Nishizawa T,Suzuki H,Kanai T,et al. Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer:a systematic review and meta-analysis[J].J Clin Biochem Nutr,2015,56(2):85-90.
[13] 何东凌,林丽梅,林春霞.胃复春片联合聚普瑞锌颗粒治疗萎缩性胃炎的疗效及对患者细胞炎性反应因子水平的影响[J].中国医院用药评价与分析,2017,17(5):651-655.
[14] 张倩倩,冯莉娟.聚普瑞锌对大鼠急性胃黏膜损伤的修复作用[J].中南大学学报(医学版),2019,44(1):22-27.
[15] 刘文徽,王昌正,马金霞,等.聚普瑞锌治疗大鼠缺血性结肠炎的实验研究[J].胃肠病学和肝病学杂志,2020,29(10):1151-1155.
PDF(689 KB)
